Trial Profile
A Phase IIb, 24 Week, Randomized, Double-blind, 3 Arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of Two Doses of Umeclidinium Bromide Administered Once-daily Via a Dry Powder Inhaler, Versus Placebo, in Participants With Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Umeclidinium (Primary) ; Fluticasone furoate; Salbutamol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 21 Jun 2018 Status changed from active, no longer recruiting to completed.
- 07 Jun 2018 Status changed from completed to active, no longer recruiting.
- 05 Jun 2018 Status changed from active, no longer recruiting to completed.